Thyme Care Raises $95M Series C Financing
				
				
			  
			
			 2024-07-16
			
			
			
			
              
			  
			
			
			
			NASHVILLE, TN, Thyme Care, the leading value-based cancer care enabler, today announced the close of a $95 million capital raise.			
			 
                  
                  With $55M in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health® Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. Banc of California will provide an additional $40M in debt financing, bringing Thyme Care's total amount raised to date to $178M.
Thyme Care is the leading value-based care enabler, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Thyme Care's approach combines a technology-enabled Care Team and seamless integration with more than 800 oncologists in Thyme Care Oncology Partners, creating a hybrid collaborative care model that guides and supports the entire patient journey. Thyme Care empowers oncologists nationwide through purpose-built tech, advanced data analytics, and virtual patient engagement, driving better care and outcomes in value-based arrangements.
				  
				  (c) by Massinvestor, Inc.  For contact info, please check out our 
about page.
 
			  
                  >> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors